Alpha Tau Medical Ltd, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $9.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen’s rating is based on several promising developments for Alpha Tau Medical Ltd. The company has initiated patient treatment in its U.S. pilot study for pancreatic cancer using Alpha DaRT, with plans to begin a similar study for glioblastoma multiforme. These studies aim to evaluate the safety and efficacy of Alpha DaRT, potentially addressing significant unmet needs in oncology.
Additionally, Alpha Tau is progressing with its U.S. pivotal trial ReSTART for recurrent cutaneous squamous cell carcinoma, expected to complete patient recruitment soon. The company is also awaiting a response from Japan’s PMDA regarding pre-market approval for Alpha DaRT in head and neck cancer. Furthermore, Alpha Tau has secured a radioactive material license in New Hampshire, paving the way for U.S. manufacturing of Alpha DaRT in 2026. These factors collectively support the Buy rating with a price target of $9.
In another report released on November 21, Piper Sandler also reiterated a Buy rating on the stock with a $5.00 price target.